Tema Etfs LLC Invests $1.10 Million in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Tema Etfs LLC bought a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 89,529 shares of the company's stock, valued at approximately $1,102,000. Tema Etfs LLC owned about 0.18% of Mineralys Therapeutics as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Mineralys Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 1,432,042 shares of the company's stock valued at $17,628,000 after purchasing an additional 68,811 shares during the last quarter. Millennium Management LLC raised its holdings in Mineralys Therapeutics by 1,015.8% in the 4th quarter. Millennium Management LLC now owns 1,101,674 shares of the company's stock valued at $13,562,000 after acquiring an additional 1,002,941 shares during the period. Jennison Associates LLC lifted its holdings in Mineralys Therapeutics by 55.4% during the 4th quarter. Jennison Associates LLC now owns 1,082,006 shares of the company's stock worth $13,319,000 after purchasing an additional 385,726 shares during the last quarter. Caligan Partners LP lifted its holdings in shares of Mineralys Therapeutics by 3.1% during the fourth quarter. Caligan Partners LP now owns 1,011,155 shares of the company's stock worth $12,447,000 after buying an additional 30,000 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its holdings in Mineralys Therapeutics by 145.8% in the 4th quarter. Integral Health Asset Management LLC now owns 875,000 shares of the company's stock valued at $10,771,000 after purchasing an additional 519,000 shares during the period. Institutional investors own 84.46% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on MLYS shares. HC Wainwright reiterated a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a research report on Tuesday, May 13th. The Goldman Sachs Group cut their target price on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Finally, Guggenheim set a $48.00 price target on Mineralys Therapeutics and gave the stock a "buy" rating in a report on Wednesday, May 14th.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. bought 1,296,296 shares of Mineralys Therapeutics stock in a transaction dated Thursday, March 13th. The stock was bought at an average cost of $13.50 per share, with a total value of $17,499,996.00. Following the completion of the acquisition, the director now directly owns 4,280,051 shares in the company, valued at approximately $57,780,688.50. The trade was a 43.45% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Samsara Biocapital Gp, Llc purchased 600,000 shares of Mineralys Therapeutics stock in a transaction that occurred on Thursday, March 13th. The shares were bought at an average price of $13.50 per share, with a total value of $8,100,000.00. Following the transaction, the insider now owns 5,674,916 shares of the company's stock, valued at $76,611,366. This trade represents a 11.82% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 104,579 shares of company stock valued at $1,534,353. Corporate insiders own 25.56% of the company's stock.

Mineralys Therapeutics Stock Up 3.5%

Mineralys Therapeutics stock traded up $0.56 during mid-day trading on Wednesday, hitting $16.66. 708,003 shares of the stock were exchanged, compared to its average volume of 480,548. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -4.58 and a beta of -0.30. Mineralys Therapeutics, Inc. has a 12 month low of $8.24 and a 12 month high of $18.38. The firm's fifty day simple moving average is $14.39 and its two-hundred day simple moving average is $12.50.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. As a group, analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current fiscal year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.